Cipla Limited — Q1 FY27 earnings call

Call held 23 Jul 2026

Management summary

Cipla reported its highest-ever Q1 FY27 revenue of INR 7,119 crores, up 2% YoY (4% adjusted), driven by strong performance in India and North America. The EBITDA margin stood at 16.7%, impacted by one-time inventory write-offs and war-related costs, but management expects sequential improvement towards its FY27 target of 18.5-20%. The company reaffirmed its $1 billion US exit run rate target for FY27, supported by key respiratory and peptide launches.

Highlights

  • Highest ever Q1 revenue of INR 7,119 crores, up 2% YoY (4% adjusted for accounting change).

  • One India business achieved its highest ever quarterly revenue with 12% YoY growth.

  • Branded prescription business in India grew 15.4% as per IQVIA data, with chronic portfolio mix strengthening to 60.4%.

  • North America revenue reached $162 million, with Cipla holding the #1 position in US Albuterol MDI market (21% share).

  • Net cash equivalent balance stood at INR 9,494 crores as of June 30, 2026, after dividend payment.

Concerns

  • EBITDA margin at 16.7% was impacted by higher-than-normal inventory write-offs and war-related costs (1-2% of revenue).

  • South Africa revenue was impacted by the loss of a tender, with continued impact expected in coming quarters.

  • Current EBITDA margin is acknowledged to be below the company's steady-state level due to new product launch investments.

Key financials

  1. Revenue ₹7,119 Cr +2%YoY
  2. EBITDA Margin 16.7%
  3. PAT ₹789 Cr
  4. R&D Spend ₹486 Cr
  5. R&D % of Revenue 6.8%
  6. Gross Margin (after material cost) 62.5%

What they filed

Q1 FY27: revenue up 0.6%, net profit down 33.8% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue4,775 4,971 4,798 5,046 5,226 +9%4,498 −10%4,210 −12%5,078 +1%
EBITDA1,438 1,662 1,319 1,624 1,523 +6%721 −57%567 −57%1,086 −33%
Net profit1,178 1,438 1,485 1,303 1,211 +3%617 −57%385 −74%862 −34%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • One India
    12% Revenue Growth
  • Branded Prescription (India)
    15.4% Growth (IQVIA)
  • North America
    162 Mn Revenue
  • South Africa (Private Market)
    6.5% Growth
  • EMEU
    5% Revenue Growth

Capital allocation

high confidence
  • Debt Gross ₹600 Cr
    As of 30 June, 2026, the debt on our balance sheet, including lease liabilities, stood at INR600 crores with net cash equivalent balance at INR9,494 crores
  • Returns FYTD ₹1,050 Cr
  • Liquidity Cash ₹9,494 Cr
    As of 30 June, 2026, the debt on our balance sheet, including lease liabilities, stood at INR600 crores with net cash equivalent balance at INR9,494 crores

Guidance & targets

Revenue

  • US Segment Exit Run Rate Revenue · FY27 · High confidence $1 billion
    And that is the approval of these will give us a line of sight towards that $1 billion exit rate.

    — Achin Gupta

Margin

  • EBITDA Margins Margin · FY27 · High confidence 18.5% to 20%
    Yes. So, broadly unchanged, Damayanti. [referring to 18.5% to 20% for FY27]

    — Ashish Adukia

Product Launch

  • Ventolin Full Ramp-up Product Launch · end of the financial year · Medium confidence Full ramp-up
    So that work is ongoing. We started supplying at the current scale, but I think that will go towards the end of the financial year.

    — Achin Gupta

What to watch in Q2 FY27

US $1 billion exit run rate for FY27

Next quarter and subsequent quarters towards FY27
Current $162 million revenue in Q1 FY27
Target Progress towards $250 million quarterly run rate

Why it matters

Key indicator of success for major US product launches and overall US business growth strategy.

I think, the way to look at it is growth from new products, because the base is not large enough to provide that kind of delta. But the new products are pretty large. So, basis the successful approval and launch of these and the scale-up of Ventolin in the coming quarters, we will be able to get that visibility.

Risks & concerns

  • Higher-than-normal inventory write-offs

    medium

    One-time inventory charges were higher than normalized, impacting gross margins.

    there has been a little higher than a normalized that we budget for, and that is why I called it out that there is a one-time, kind of, an inventory charge that is there.

    Management acknowledged

  • War-related costs impacting gross margins

    medium

    Estimated 1% to 2% of revenue impact on overall cost due to war.

    But if you could assume about 1% to 2% of revenue in that kind of a range for the overall cost impact due to war.

    Management acknowledged

  • Continued impact from South Africa tender loss

    medium

    A lost tender from the previous year will continue to impact South Africa's reported revenue in coming quarters.

    last year, we lost a tender, which has a supply plan that is impacting this year. So, in the coming quarters also, there will be that continuation of that impact that will come through.

    Both acknowledged

  • Regulatory delays for Lanreotide

    medium

    Timing for Lanreotide regulatory approvals and site transfer is fluid and not included in Q4 projections.

    timing is a little bit fluid because both have dependence on the regulatory approvals. So, as we get more certainty on this, we will guide towards it. But at this point, we're not including that as part of our Q4 projections.

    Both acknowledged

  • Current EBITDA margin below steady state

    medium

    Current margin level is below the company's steady state due to new product launch investments, but improvement is expected.

    I think right now, we would refrain from providing a guidance for next year. But I think direction for us is we recognize that the current margin level is below our steady state. So, we will improve it.

    Both acknowledged

Q&A highlights

7 direct
Impact of accounting change on growth rates Partial
if you go through the note, Saion, you'll find the numbers mentioned out there for the previous Y-o-Y quarter as well. So, you'll be able to calculate the growth and the growth would be somewhere around 4% if you just adjust for the previous year number as well.

Clarifies that the reported 2% YoY revenue growth is 4% on an adjusted basis, primarily due to changes in South Africa's accounting presentation.

Asked by Saion Mukharji

South Africa performance and tender loss Direct
on tender, how you have to see it is that when we look at tenders. So, it needs to be accretive to our margins, then accordingly, we bid for these tenders. So, unfortunately, last year, we lost a tender, which has a supply plan that is impacting this year. So, in the coming quarters also, there will be that continuation of that impact that will come through.

Explains the decline in South Africa's reported revenue is due to a lost tender from the previous year, with the impact continuing in subsequent quarters.

Asked by Saion Mukharji

US launch pipeline and $1 billion exit run rate for FY27 Direct
we are seeing three respiratory launches, which are significant in addition to the Ventolin approval that we've got and one peptide, which is large, right... And that is the approval of these will give us a line of sight towards that $1 billion exit rate.

Reaffirms the $1 billion US exit run rate target for FY27, driven by key respiratory and peptide launches, including Ventolin.

Asked by Damayanti Kerai

Gross margin trajectory, inventory write-offs, and inflation impact Direct
overall, if you look at it as per current estimate, and it's very difficult to give a very firm guidance out there, because the things are evolving. But if you could assume about 1% to 2% of revenue in that kind of a range for the overall cost impact due to war... there has been a little higher than a normalized that we budget for, and that is why I called it out that there is a one-time, kind of, an inventory charge that is there.

Explains the factors impacting gross margin this quarter, including war-related costs (1-2% of revenue) and higher-than-normal inventory write-offs.

Asked by Vishal Manchanda

Ventolin full ramp-up timeline in the US Direct
So that work is ongoing. We started supplying at the current scale, but I think that will go towards the end of the financial year.

Provides a timeline for the full commercial scale-up of generic Ventolin in the US.

Asked by Vishal Manchanda

Competitive landscape for new US launches (Ventolin, peptide) Direct
on Ventolin, right now, we have the CGT. So, we have exclusivity for six months. We are not aware of competition at this point in time... And after that also, we would not expect it to be highly crowded, because of the complexity of this development itself. And similar case for the peptide as well, we have a very good chance of being the first and potentially being the only one.

Highlights the competitive advantage and market share potential for key new US product launches due to exclusivity and complexity.

Asked by Vivek Agrawal

Current EBITDA margin level and path to improvement Direct
I think right now, we would refrain from providing a guidance for next year. But I think direction for us is we recognize that the current margin level is below our steady state. So, we will improve it. And we've already mentioned 18.5% to 20% as the guidance for this year. So, you can expect improvements in the coming quarters.

Acknowledges that current margins are below the steady state and reiterates the FY27 target of 18.5-20%, expecting sequential improvement.

Asked by Vivek Agrawal

Regulatory status of New York facility and impact on launches Direct
Only the smaller ones. That unit does solid oral. So those are not the biggest launches, not part of the three respi that we spoke about. Those have already been inspected.

Clarifies that the single observation at the New York facility will not impact the major upcoming US respiratory launches.

Asked by Damayanti Kerai

2 min read 6 chapters

Detailed narrative

Strong Q1 FY27 Revenue Performance

Cipla reported its highest-ever Q1 revenue of INR 7,119 crores, marking a 2% year-on-year growth. On an adjusted basis, accounting for a change in financial presentation primarily in South Africa, the growth would be approximately 4%. This strong start to the fiscal year reinforces the company's business fundamentals and diversified portfolio, strengthening confidence in sustaining long-term growth.

Robust India Business Growth and Chronic Focus

The 'One India' business achieved its highest-ever quarterly revenue with a 12% year-on-year growth, reflecting strong performance across key therapies. The branded prescription segment demonstrated significant momentum, growing 15.4% as per IQVIA data, with the overall chronic mix strengthening to 60.4% year-on-year. Key therapies like Respiratory, Anti-diabetes, Cardiac, and Urology all registered strong double-digit growth, driven by volume expansion and new product launches.

North America Performance and Strategic Launches

North America generated $162 million in revenue, with Cipla maintaining its #1 position in the overall U.S. Albuterol MDI market with a 21% share. A key highlight was the successful launch of generic Ventolin, with commercial shipments commencing and volumes expected to increase towards the end of the financial year. The company anticipates continued sequential growth, supported by upcoming launches including three significant respiratory assets and one large peptide product, aiming for a $1 billion exit run rate for FY27.

Margin Headwinds and Outlook

The reported EBITDA margin stood at 16.7% for the quarter, impacted by higher-than-normal inventory write-offs and war-related costs, estimated at 1-2% of revenue. Management acknowledged that the current margin level is below its steady state, primarily due to investments in new product launches and facility readiness. However, they reiterated the FY27 EBITDA margin guidance of 18.5% to 20%, expecting gradual sequential improvement in coming quarters driven by new products, facility utilization, and cost optimization.

Regulatory Updates and South Africa Challenges

On the regulatory front, Cipla received a VAI classification for its Verna, Goa facility after a routine GMP inspection. The Invagen facility in New York received one Form 483 observation, which the company is committed to addressing within the stipulated timeline. In South Africa, the business experienced a decline in tender revenue due to a lost tender from the previous year, with this impact expected to continue in subsequent quarters, although the private market grew healthily at 6.5%.

Capital Allocation and Liquidity Position

The company reported a healthy net cash equivalent balance of INR 9,494 crores as of June 30, 2026, after a dividend payment of INR 1,050 crores. Gross debt, including lease liabilities, stood at INR 600 crores. R&D investments for the quarter were INR 486 crores, or 6.8% of revenue, primarily directed towards product filings and key development programs. Cipla continues to explore M&A opportunities for differentiated products in the US and Europe, while focusing on organic growth through increased capex and internal pipeline assets.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls